Vernakalant is a new antiarrhythmic drug that acts selectively in the atrium, targeting atrial specific potassium and sodium channels. The efficacy and safety in terminating recent-onsetor postoperation atrial flbrillation and maintaining sinus rhythm in patients with recurrent atrial flbrillation had been evaluated in serial clinical trials. Further large-scale researches are warranted to confirm these findings and further inform clinical practice.
语种：
中文
第一作者：
第一作者机构：[1]Department of Cardiology, Centre for Atrial Fibrillation, Beijing Anzhen Hospital, Beijing 100029, China
推荐引用方式(GB/T 7714)：
Ma C.-S,Chen K.Progress toward the clinical application of vernakalant: A new antiarrhythmic agent[J].2012,21(15):
